Healthcare Professionals

ACE Clinical Guidances (ACGs)

ACGs
View Guidances

ACE CUES

ACE CUES_Logo_web

Find Out More

ACE Drug Guidances

DG
View Guidances

ACE Medical Technology Guidances

MG
View Guidances

ACE Horizon Scanning

HS

Find Out More
Published on 02 Jan 2024
Last Updated on 02 Jan 2024
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion, in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin and prednisone, for previously untreated diffuse large B-cell lymphoma (DLBCL) with an international prognostic index (IPI) score of 3 to 5.

Funding status

Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indication from 1 March 2024.

MAF assistance does not apply to previously untreated diffuse large B-cell lymphoma in patients with an IPI score below 3.

Clinical indications, subsidy class and MediShield Life claim limits for polatuzumab vedotin are provided in the Annex.


Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma (Published 2 Jan 2024) PES Polatuzumab vedotin for previously untreated diffuse large B cell lymphoma (Published 2 Jan 2024)